Small-cell neuroendocrine tumor of the bladder: A rare disease in a low-risk woman

Jordan Sarver a, *, Mark Memo b

a Ohio University Heritage College of Osteopathic Medicine, Athens, OH, 45701, United States
b NEOurology, 7430 Southern Blvd, Boardman, OH, 44512, United States

A R T I C L E   I N F O
Keywords:
Bladder cancer
Neuroendocrine tumor
Oncology
Neoadjuvant chemotherapy

A B S T R A C T
Bladder cancer is the fourth most common malignancy in men and ninth most in woman. Most bladder cancers are urothelial and the neuroendocrine sub-types make up 0.5–1.0% of cases. Here we present a 70-year-old female with poorly differentiated small cell carcinoma of the bladder who complains of an extensive history of gross hematuria. She was started on a neoadjuvant chemotherapy regimen of 21-day Etoposide with Carboplatin and radical cystectomy. More work needs to be done when it comes to the best treatment method for this rare cohort of patients.

1. Introduction
Bladder cancer is the fourth most common malignancy in men and ninth most in woman. Most bladder cancers are urothelial and the neuroendocrine sub-types make up 0.5–1.0% of cases. Neuroendocrine tumors are divided into small cell carcinoma (SCC) and large cell neuroendocrine carcinoma. Most neuroendocrine tumors of the bladder are mixed with other subtypes. Due to several factors, SCC often presents more aggressively and carries a worse prognosis for patients.

Here we present a 70-year-old female with poorly differentiated SCC of the bladder who complains of an extensive history of gross hematuria.

2. Case presentation
A 70-year-old female presented to the urology clinic complaining of 6–12 months of hematuria. She has a past medical history of a thyroid nodule, hypothyroidism, fibrocystic breast disease, hypertension, and stage IIIb chronic kidney disease. She admits to a family history of pancreatic, breast, and kidney cancer. She has never undergone surgical evaluation for any genitourinary cancers. She denies any current or previous smoking or alcohol use. Today the patient only complains of continnal hematuria, denying all other symptoms. Initial laboratory examination showed a complete blood count within normal limits. Metabolic examination showed an elevated creatinine of 1.30, Alkaline phosphatase of 96, and mildly elevated liver enzymes (AST 40, ALT 42). Urine cytology was obtained and showed atypical urothelial cells, inconclusive for malignancy. Follow-up CT scan was obtained, reading a 4.4 × 1.6 cm lobulated mass involving the dome of the urinary bladder. No obstructive uropathy was noted. Small lymph nodes were noted along the iliac chain measuring 1 cm in the left external iliac chain. She then consented and was taken to the operating room for a transurethral resection of the bladder tumor (TURBT).

She presented to the operating room for cystoscopy and TURBT. On examination, there was a substantial amount of necrotic tissue present on the dome of the bladder. A biopsy of the area was thought to be necrosis due to the patient’s history of laser therapy treatment for incontinence. Pathology revealed small cell neuroendocrine carcinoma and invasive high-grade carcinoma (Fig. 3) with squamous differentiation. The viable TURBT specimen was approximately 80% small cell carcinoma in etiology. She was sent referral for medical oncology. PET CT per medical oncology revealed a bladder tumor with SUV 17.4, left common iliac lymph node measuring SUV 15.6, and adjacent left external iliac lymph node measuring 4.1 × 2.5 cm with SUV 20.1. She will proceed for neoadjuvant chemotherapy with a 21-day Etoposide with Carboplatin. After completion of chemotherapy, she will likely undergo local treatment with radical cystectomy. The patient was consented for cystectomy and underwent the procedure. Negative margins were confirmed and she recovered from the procedure well without complications to date.

* Corresponding author. Ohio University College of Osteopathic Medicine, 191 W Union St, Athens, OH, 45701, United States.
E-mail addresses: js492517@ohio.edu, js492517@ohio.edu (J. Sarver), marcomemo44@msn.com (M. Memo).

https://doi.org/10.1016/j.eucr.2021.101923
Received 27 September 2021; Received in revised form 25 October 2021; Accepted 27 October 2021
Available online 29 October 2021
2214-4420/© 2021 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
3. Discussion

SCC of the bladder is a rare disease with little clinical evidence on effective treatment.\textsuperscript{1} For this reason, careful patient work-up and treatment should be considered. Similar to urothelial cancer, patients with SCC will likely present with painless hematuria.\textsuperscript{4} A proper history and physical exam can guide clinical suspicion for this cancer. Smoking history is important to note, as this has been a well-described risk factor for all types of bladder malignancy.\textsuperscript{1} Cystoscopy is done to visually assess the tumor burden.\textsuperscript{3} Biopsy of the tissue via TURBT is needed to distinguish this rare tumor sub-type from other types of bladder malignancies.\textsuperscript{3} Upon histologic examination, the tissue will stain with keratin, synaptophysin, and chromogranin to distinguish the cancer as SCC.\textsuperscript{2}

Treatment regimens for local disease can range from TURBT, partial cystectomy, and radical cystectomy depending on tumor grade and stage.\textsuperscript{4} TURBT alone was found to be inadequate for tumor burden for these patients.\textsuperscript{4} This leaves radical cystectomy as the preferred option for treatment.\textsuperscript{4} Unfortunately, these tumors tend to be aggressive and may present with locally advanced disease in at least 70% of cases.\textsuperscript{2} For this reason, neoadjuvant or adjuvant chemotherapy options have been explored.\textsuperscript{4} This decision may be dependent on the histological type of SCC.\textsuperscript{4} Mixed SCC can respond better to MVAC (methotrexate, vinblastine, adriamycin, cisplatin) therapy.\textsuperscript{4} Pure SCC will likely respond better to a cisplatin/carboplatin and etoposide therapy.\textsuperscript{4} Radiation therapy may play a role for patients with local disease without progression.\textsuperscript{4} Overall, most patients seem to benefit from neoadjuvant chemotherapy with radical cystectomy.\textsuperscript{2} A retrospective study by Quek et al. supported this by concluding that neoadjuvant chemotherapy followed by radical cystectomy showed a better 5-year overall survival for patients compared to radical cystectomy alone.\textsuperscript{5}

Our patient presented with concern for metastatic disease to local lymph nodes. Medical oncology started her on a neoadjuvant chemotherapy regimen of 21-day Etoposide with Carboplatin. Radical cystectomy will be undergone after this chemotherapy is complete. Follow-up will be routine with CT scans to assess for any further progression or recurrence of disease.

This case was a unique example exploring the presentation of a rare subtype of bladder cancer in a female. Although few case reports exist, it is important to inform the provider of this potential diagnosis. For this to present in a female who does not smoke emphasizes the importance to keep a broad differential and aggressively treat this rare cancer.

4. Conclusion

Bladder cancer remains a prevalent disease in men and women world-wide. The workup and treatment of this disease is guided by tumor grade and stage. A small, unique sub-set of patients will present with the more aggressive neuroendocrine sub-type. In this rare population, proper treatment is especially important due to its likelihood of advanced disease at presentation. This case was a unique presentation of a woman with no smoking history who presented with small cell neuroendocrine carcinoma and invasive high-grade carcinoma with squamous differentiation. Her treatment consisted of neoadjuvant chemotherapy with radical cystectomy. Overall, this case emphasizes the importance for providers to keep these bladder tumor variations in mind. More work needs to be done when it comes to the best treatment method for this rare cohort of patients.

Declaration of competing interest

None of the authors has a conflict of interest to report, real or
perceived, that would influence the results of this study. All authors contributed to a significant portion of this manuscript.

References

1. Sehgal SS, Wein AJ, Bing Z, Malkowicz SB, Guzzo TJ. Neuroendocrine tumor of the bladder. Rev Urol. 12(4):197-201.
2. Masood B, Iqbal N, Iqbal W, Masood Y, Khalid Akbar M, Mamoon N. Small-cell neuroendocrine carcinoma of the urinary bladder: a case report. Int J Health Sci. 2020; 14(2):53–55.
3. Kouba E, Chen L. Neuroendocrine tumors of the urinary bladder according to the 2016 world health organization classification: molecular and clinical characteristics: neuroendocrine tumors of the bladder. Endocr Pathol. 2016;27(3).
4. Ghervan L, Zaharie A, Ene B, Elee F. Small-cell carcinoma of the urinary bladder: where do we stand? Clinul Med. 2017;90(1):13–17.
5. Quek M, Nichols P, Yamzon J, et al. Radical cystectomy for primary neuroendocrine tumors of the bladder: the university of southern California experience. J Urol. 2005; 174(1):93–96.